Supernus Pharmaceuticals - SUPN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.00
  • Forecasted Upside: 21.12 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$33.85
▲ +0.57 (1.71%)

This chart shows the closing price for SUPN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Supernus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SUPN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SUPN

Analyst Price Target is $41.00
▲ +21.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Supernus Pharmaceuticals in the last 3 months. The average price target is $41.00, with a high forecast of $44.00 and a low forecast of $38.00. The average price target represents a 21.12% upside from the last price of $33.85.

This chart shows the closing price for SUPN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Supernus Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/6/2022Piper SandlerBoost Target$38.00Low
8/31/2022Piper SandlerBoost TargetOverweight$33.00 ➝ $38.00Low
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$40.00 ➝ $44.00High
4/13/2021Jefferies Financial GroupUpgradeHold ➝ Buy$25.00 ➝ $40.00High
2/3/2021Piper SandlerBoost TargetOverweight$30.00 ➝ $35.00Low
6/16/2020Piper SandlerUpgradeNeutral ➝ Overweight$25.00 ➝ $31.00High
6/15/2020Jefferies Financial GroupInitiated CoverageHold$24.00Low
4/30/2020Piper SandlerBoost TargetCautious ➝ Neutral$17.00 ➝ $25.00High
4/16/2020Stifel NicolausLower TargetHold$25.00 ➝ $24.00Medium
11/8/2019Berenberg BankDowngradeBuy ➝ HoldMedium
11/7/2019Stifel NicolausDowngradeBuy ➝ Hold$55.00 ➝ $23.00High
11/6/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$46.00 ➝ $23.00High
8/30/2019Jefferies Financial GroupSet TargetBuy$46.00Low
8/7/2019CowenSet TargetBuy$50.00Low
8/7/2019Stifel NicolausSet TargetBuy$55.00Low
8/7/2019MizuhoReiterated RatingBuyHigh
5/17/2019MizuhoReiterated RatingBuyLow
5/8/2019Cantor FitzgeraldSet TargetBuy$60.00Medium
4/17/2019MizuhoReiterated RatingBuy$63.00High
3/28/2019MizuhoReiterated RatingBuy$63.00Low
3/4/2019B. RileySet TargetBuy$65.00High
2/27/2019Cantor FitzgeraldReiterated RatingBuy$57.00High
1/16/2019Piper Jaffray CompaniesSet TargetHold$44.00Low
1/10/2019Cantor FitzgeraldSet TargetBuy$57.00Low
12/17/2018MizuhoBoost TargetBuy ➝ Buy$61.00 ➝ $63.00Medium
12/14/2018Cantor FitzgeraldSet TargetBuy$57.00Medium
11/30/2018CowenSet TargetBuy$55.00High
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/12/2018B. RileyLower TargetBuy ➝ Buy$68.00 ➝ $65.00Low
11/7/2018Cantor FitzgeraldSet TargetBuy$57.00High
10/22/2018Cantor FitzgeraldSet TargetBuy$56.00Medium
10/4/2018Cantor FitzgeraldSet TargetBuy$56.00Low
9/17/2018MizuhoInitiated CoverageBuy$61.00High
9/14/2018Cantor FitzgeraldReiterated RatingBuy$56.00Low
8/28/2018Piper Jaffray CompaniesSet TargetHold$44.00Low
8/9/2018Jefferies Financial GroupBoost TargetBuy ➝ Buy$55.00 ➝ $58.00High
8/9/2018Piper Jaffray CompaniesReiterated RatingHold$44.00Medium
8/8/2018Cantor FitzgeraldSet TargetBuy$56.00Medium
7/25/2018Piper Jaffray CompaniesReiterated RatingHold$46.00High
7/8/2018Piper Jaffray CompaniesSet TargetHold$47.00Low
7/2/2018Piper Jaffray CompaniesSet TargetHold$47.00High
5/25/2018Stifel NicolausBoost TargetBuy ➝ Buy$50.00 ➝ $60.00Medium
2/1/2018Berenberg BankInitiated CoverageBuy$66.00High
1/18/2018B. RileyReiterated RatingBuy ➝ Buy$54.00High
12/28/2017B. RileyBoost TargetBuy ➝ Buy$50.00 ➝ $54.00High
12/4/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$47.00High
11/20/2017B. RileyReiterated RatingBuy$50.00N/A
11/7/2017Stifel NicolausUpgradeHold ➝ Buy$47.00N/A
11/6/2017B. RileyReiterated RatingBuy$53.00 ➝ $50.00N/A
11/3/2017SunTrust BanksReiterated RatingBuy$61.00N/A
10/29/2017Piper Jaffray CompaniesSet TargetHold$41.00N/A
10/23/2017CowenSet TargetBuy$50.00N/A
10/19/2017FBR & Co.Initiated CoverageBuy ➝ Buy$53.00N/A
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/5/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/5/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/3/2022
  • 6 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/2/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Supernus Pharmaceuticals logo
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $33.85
Low: $33.31
High: $34.33

50 Day Range

MA: $33.44
Low: $30.55
High: $35.51

52 Week Range

Now: $33.85
Low: $24.95
High: $36.08

Volume

723,924 shs

Average Volume

382,826 shs

Market Capitalization

$1.81 billion

P/E Ratio

33.52

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Supernus Pharmaceuticals?

The following Wall Street research analysts have issued reports on Supernus Pharmaceuticals in the last year: Jefferies Financial Group Inc., Piper Sandler, StockNews.com, and TheStreet.
View the latest analyst ratings for SUPN.

What is the current price target for Supernus Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Supernus Pharmaceuticals in the last year. Their average twelve-month price target is $41.00, suggesting a possible upside of 21.1%. Jefferies Financial Group Inc. has the highest price target set, predicting SUPN will reach $44.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $38.00 for Supernus Pharmaceuticals in the next year.
View the latest price targets for SUPN.

What is the current consensus analyst rating for Supernus Pharmaceuticals?

Supernus Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SUPN will outperform the market and that investors should add to their positions of Supernus Pharmaceuticals.
View the latest ratings for SUPN.

What other companies compete with Supernus Pharmaceuticals?

How do I contact Supernus Pharmaceuticals' investor relations team?

Supernus Pharmaceuticals' physical mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company's listed phone number is (301) 838-2500 and its investor relations email address is [email protected] The official website for Supernus Pharmaceuticals is www.supernus.com. Learn More about contacing Supernus Pharmaceuticals investor relations.